SCHEMBL3565802

SCHEMBL3565802

COc1ncc(-c2ccncc2F)c(OC)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 1/20 0.42
QPCTL Q9NXS2 1/20 0.42
CYP1A2 P05177 1/20 0.41
METAP2 P50579 1/20 0.41
NUDT1 P36639 2/20 0.40
HASPIN Q8TF76 2/20 0.39
ROCK2 O75116 1/20 0.37
RPS6KA3 P51812 2/20 0.36
CRHR1 P34998 1/20 0.36
PLAU P00749 1/20 0.36
PIK3CD O00329 2/20 0.36
PIK3C3 Q8NEB9 1/20 0.36
DAPK3 O43293 1/20 0.35
PLK1 P53350 1/20 0.35
PLK3 Q9H4B4 1/20 0.35
PLK2 Q9NYY3 1/20 0.35
ABL1 P00519 1/20 0.35
EGFR P00533 1/20 0.35
HCK P08631 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3570023 0.80 CYP11B1 (0.46) QPCTQPCTLCYP1A2METAP2HASPIN
SCHEMBL3560176 0.76 QPCT (0.42) QPCTQPCTLCYP1A2METAP2CRHR1
SCHEMBL3570149 0.73 RECQL (0.49) QPCTQPCTLCYP1A2METAP2HASPIN
SCHEMBL3562325 0.73 QPCT (0.42) QPCTQPCTLCYP1A2METAP2CRHR1
SCHEMBL2511301 0.73 QPCT (0.39) QPCTQPCTLCYP1A2METAP2CRHR1
SCHEMBL31301232 0.72 NUDT1 (0.57) CYP1A2METAP2NUDT1ROCK2RPS6KA3
SCHEMBL10304998 0.72 QPCT (0.44) QPCTQPCTLCYP1A2METAP2ABL1
SCHEMBL15624621 0.71 QPCT (0.43) QPCTQPCTLCYP1A2METAP2HASPIN
SCHEMBL30961410 0.70 QPCT (0.44) QPCTQPCTLCYP1A2METAP2CRHR1
SCHEMBL3564444 0.70 QPCT (0.45) QPCTQPCTLCYP1A2METAP2CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007750-B1 AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LTD (GB) 2013-08-21 EP disclosed
US-7727988-B2 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2010-06-01 US disclosed
US-7727988-B2 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2010-06-01 US disclosed
US-7727988-B2 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2010-06-01 US disclosed
CN-101460485-A Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptor GLAXO GROUP LTD (GB) 2009-06-17 CN disclosed
EP-2007750-A1 AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2008-12-31 EP disclosed
US-20070249642-A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2007-10-25 US disclosed
US-20070249642-A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2007-10-25 US disclosed
US-20070249642-A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione GLAXO GROUP LIMITED (GB) 2007-10-25 US disclosed
WO-2007113232-A1 AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2007-10-11 WO disclosed
WO-2007113232-A1 AZABICYCLO [3. 1. 0] HEXYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS GLAXO GROUP LIMITED (GB) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249642-A1 Azabicyclo[3.1.0]hex-3-yl}alkyl)pyrimidinedione AZI2, NT5C3B, CYP1B1 QPCT 2929/4885QPCTL 3866/4885CYP1A2 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.